These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 20467883

  • 1. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
    Hui EP, Lui VW, Wong CS, Ma BB, Lau CP, Cheung CS, Ho K, Cheng SH, Ng MH, Chan AT.
    Invest New Drugs; 2011 Dec; 29(6):1123-31. PubMed ID: 20467883
    [Abstract] [Full Text] [Related]

  • 2. Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts.
    Wang D, Jiang Z, Zhang L.
    Med Oncol; 2012 Jun; 29(2):600-6. PubMed ID: 21455800
    [Abstract] [Full Text] [Related]

  • 3. Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
    Pan F, Tian J, Zhang X, Zhang Y, Pan Y.
    J Cancer Res Clin Oncol; 2011 Sep; 137(9):1397-408. PubMed ID: 21796416
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo.
    Xue C, Tian Y, Zhang J, Zhao Y, Zhan J, Fang W, Zhang L.
    Drug Des Devel Ther; 2016 Sep; 10():1173-80. PubMed ID: 27042009
    [Abstract] [Full Text] [Related]

  • 5. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.
    Brooks C, Sheu T, Bridges K, Mason K, Kuban D, Mathew P, Meyn R.
    Radiat Oncol; 2012 Sep 11; 7():154. PubMed ID: 22967802
    [Abstract] [Full Text] [Related]

  • 6. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F.
    Clin Cancer Res; 2009 May 15; 15(10):3384-95. PubMed ID: 19417025
    [Abstract] [Full Text] [Related]

  • 7. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y, Zhang J, Tian Y, Xue C, Hu Z, Zhang L.
    Drug Des Devel Ther; 2015 May 15; 9():4897-907. PubMed ID: 26345996
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
    Joshi AD, Loilome W, Siu IM, Tyler B, Gallia GL, Riggins GJ.
    PLoS One; 2012 May 15; 7(10):e44372. PubMed ID: 23056179
    [Abstract] [Full Text] [Related]

  • 9. Famitinib enhances nasopharyngeal cancer cell radiosensitivity by attenuating radiation-induced phosphorylation of platelet-derived growth factor receptor and c-kit and inhibiting microvessel formation.
    Mu X, Ma J, Zhang Z, Zhou H, Xu S, Qin Y, Huang J, Yang K, Wu G.
    Int J Radiat Biol; 2015 May 15; 91(9):771-6. PubMed ID: 26073526
    [Abstract] [Full Text] [Related]

  • 10. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.
    Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, Piantelli M, Iacobelli S.
    Cancer Lett; 2008 Nov 08; 270(2):229-33. PubMed ID: 18586384
    [Abstract] [Full Text] [Related]

  • 11. Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.
    Maj E, Filip-Psurska B, Milczarek M, Psurski M, Kutner A, Wietrzyk J.
    Int J Oncol; 2018 Feb 08; 52(2):337-366. PubMed ID: 29345296
    [Abstract] [Full Text] [Related]

  • 12. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
    Park HS, Hong SK, Oh MM, Yoon CY, Jeong SJ, Byun SS, Cheon J, Lee SE, Moon du G.
    Anticancer Res; 2014 Jul 08; 34(7):3457-68. PubMed ID: 24982354
    [Abstract] [Full Text] [Related]

  • 13. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.
    Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP.
    Urol Oncol; 2009 Jul 08; 27(4):391-9. PubMed ID: 18534874
    [Abstract] [Full Text] [Related]

  • 14. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.
    Zhao YY, Tian Y, Zhang J, Xu F, Yang YP, Huang Y, Zhao HY, Zhang JW, Xue C, Lam MH, Yan L, Hu ZH, Dinglin XX, Zhang L.
    Drug Des Devel Ther; 2014 Jul 08; 8():1827-37. PubMed ID: 25336925
    [Abstract] [Full Text] [Related]

  • 15. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
    Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM.
    Mol Cancer Ther; 2003 May 08; 2(5):471-8. PubMed ID: 12748309
    [Abstract] [Full Text] [Related]

  • 16. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
    Lopergolo A, Nicolini V, Favini E, Dal Bo L, Tortoreto M, Cominetti D, Folini M, Perego P, Castiglioni V, Scanziani E, Borrello MG, Zaffaroni N, Cassinelli G, Lanzi C.
    J Clin Endocrinol Metab; 2014 Feb 08; 99(2):498-509. PubMed ID: 24276455
    [Abstract] [Full Text] [Related]

  • 17. Sunitinib mesylate inhibits proliferation of human colonic stromal fibroblasts in vitro and in vivo.
    Wang ZH, Li Q, Ruan SQ, Xiao Q, Liu Y, Hu YT, Hu LF, Chen HY, Zheng S, Zhang SZ, Ding KF.
    J Zhejiang Univ Sci B; 2014 Aug 08; 15(8):701-12. PubMed ID: 25091988
    [Abstract] [Full Text] [Related]

  • 18. Preclinical evaluation of the dual mTORC1/2 inhibitor sapanisertib in combination with cisplatin in nasopharyngeal carcinoma.
    Zhang J, Jiang Y, Yu Y, Li J.
    Eur J Pharmacol; 2022 Jan 15; 915():174688. PubMed ID: 34883074
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
    Huang Y, Tian Y, Zhao Y, Xue C, Zhan J, Liu L, He X, Zhang L.
    Cancer Commun (Lond); 2018 May 03; 38(1):15. PubMed ID: 29764490
    [Abstract] [Full Text] [Related]

  • 20. ZD1839 and cisplatin alone or in combination for treatment of a nasopharyngeal carcinoma cell line and Xenografts.
    Gu WG, Huang Y, Yuan ZY, Peng RJ, Luo HT, He ZR, Wang SS.
    Asian Pac J Cancer Prev; 2013 May 03; 14(3):1787-90. PubMed ID: 23679274
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.